The role of miRNA in IBS pathogenesis, diagnosis and therapy: The latest thought.

Irritable bowel syndrome (IBS) affects millions of people worldwide, causing digestive discomfort, pain, and changes in bowel habits. Despite being so common, doctors still don't fully understand what causes IBS, and there are limited tests to diagnose it accurately or medications that work well for everyone. Recent research is exploring a new avenue: tiny molecules called microRNAs (miRNAs) that help control how our genes work. Scientists have discovered that people with IBS have different levels of certain miRNAs in their intestinal tissue and blood compared to healthy individuals. These miRNAs appear to play an important role in how IBS develops by affecting inflammation, gut sensitivity, and communication between the gut and brain. This research review examined current studies on miRNAs in IBS patients and found that these molecules could potentially serve three important purposes: helping scientists better understand what causes IBS, providing new biomarkers for more accurate diagnosis through simple blood tests, and offering new treatment targets for future therapies. For patients considering acupuncture for IBS symptoms, this research is relevant because acupuncture has been shown to affect gene expression and inflammatory pathways in the body, which may overlap with these miRNA mechanisms. Understanding the biological processes behind IBS can help both patients and practitioners appreciate how different therapies, including acupuncture, might work at a cellular level to relieve symptoms. If you're considering acupuncture for IBS, seek a licensed acupuncturist with experience treating digestive disorders.

This literature review examines the role of microRNAs (miRNAs) in irritable bowel syndrome pathophysiology, diagnosis, and treatment. MiRNAs are 20-24 nucleotide non-coding RNA molecules that regulate post-transcriptional gene silencing. Research demonstrates differential expression of specific miRNAs in colonic tissue and peripheral blood of IBS patients compared to controls. These miRNAs appear to mediate critical pathophysiological processes including visceral hypersensitivity, gut-brain axis dysfunction, immune activation, and intestinal barrier integrity. The review identifies miRNAs as potential biomarkers for IBS diagnosis and therapeutic targets. Clinical relevance: Understanding miRNA dysregulation in IBS provides insight into molecular mechanisms that may be modulated by acupuncture treatment. Previous research shows acupuncture influences gene expression, inflammatory cytokines, and neuroimmune pathways, potentially intersecting with miRNA regulatory networks. No specific sample sizes or effect sizes were provided in this review article. Practitioners treating IBS should remain informed about emerging molecular mechanisms to better understand how integrative approaches may achieve therapeutic effects.